An investigation by Bloomberg News found that many widely used cancer drugs approved under expedited rules have not proven to extend patients’ lives, despite soaring costs. The “Cancer Capitalism” series revealed a system where drug companies, hospitals, and some doctors profit from high prices, excessive dosing, and weak oversight—often leaving patients with severe side effects, financial strain, and questionable benefits.
